Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06103487 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long Term Follow-Up for RGX-111

StatusEnrolling by Invitation
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment target: 7 to 21 Secondary endpoints: 1 to 9 · Study description shortened, about 2 wordsv3 Show 2 more changesShow less
    • Secondary endpoints: 1 to 9
    • Study description shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  2. Enrollment target: 8 to 7 Study sites: 3 to 2 · Secondary endpoints: 9 to 1 · Study description shortened, about 2 wordsv2 Show 3 more changesShow less
    • Study sites: 3 to 2
    • Secondary endpoints: 9 to 1
    • Study description shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
RGX-111-5101 is a long-term follow up study that evaluates the long-term safety and efficacy of RGX-111 in participants who have received RGX-111 (a gene therapy intended to deliver a functional copy of the alpha-L-iduronidase gene (IDUA) to the central nervous system) in a separate parent study.
Trial Details
NCT Number NCT06103487
Lead Sponsor REGENXBIO Inc.
Conditions Mucopolysaccharidosis I
Enrollment 21 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov